Ekram Fateen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekram Fateen has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Amr Gouda
Biochemical Genetics Department, National Research Centre, Dokki, Egypt
4 shared publications - Mona S. Aglan
Clinical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt
4 shared publications - Samia Ali Temtamy
National Research Centre, Cairo, Egypt
3 shared publications - Zeinab Y. Abdallah
Human Genetics and Genome Research Institute, Biochemical Genetics Department, National Research Centre, Cairo, Egypt
3 shared publications - Hanan Abd El Mawgoud
Department of Pharmacology and Toxicology, College of Pharmacy, Hail University, Hail, Kingdom of Saudi Arabia
2 shared publications - Khalda Sayed Amr
Division of Medical Molecular Genetics, National Research Center, Cairo, Egypt
2 shared publications
Latest Publications
- Open Access
- 29 October 2025
- Published by Egyptian Knowledge Bank in Egyptian Pharmaceutical Journal
Genetic insights and therapeutic implications in Egyptian patients with Fabry Disease
BackgroundFabry disease (FD) is an X-linked lysosomal storage disorder resulting from pathogenic variants in the α-galactosidase (GLA) gene, leading to deficiency in “α-galactosidase A” (GLA) activity. This enzyme deficiency leads to progressive accumulation of glycosphingolipids in various tissues and organs. ObjectivesThis study aims to clinical, biochemical, and molecular diagnosis for three unrelated Egyptian families with Fabry disease.Patients and methods The GLA enzyme activity was measured in 3 males from 3 unrelated families. The GLA activity was measured by using the fluorogenic substrate “4-methylumbelliferyl-α-D-galactopyranoside” and the diagnosis of FD was established by GLA deficiency. The patients presented with variable renal, cardiac, ocular and dermatological manifestations. History and pedigree was done for 3 families. Molecular analysis of GLA gene was performed for 3 patients, the mother, two daughters and the sister of P1, the mother, wife and daughter of P2, and the mother, brother, and cousin of P3. Genetic tests by PCR of the gene-coding region followed by Sanger sequencing. Results We revealed 3 previously reported GLA variants in 3 Fabry families. Family 1, a nonsense variant c.627G>A, p.W209* was identified in patient 1 and in one of the patient’s daughters. In Family 2, a splice-site variant c.370-2A>G was detected in patient 2 and in his mother and daughter. In Family 3, a missense variant c.334C>T, p.R112C was detected in patient 3.Conclusion This study expands the molecular genetic spectrum of the GLA gene associated with Egyptian FD patients. Our findings highlighted the importance of early diagnosis, proper genetic counseling and therapy for FD patients. To the best of our knowledge, the present study is the first delineating the GLA variant profile in Egyptian FD patients. The patients are currently receiving Enzyme Replacement Therapy (ERT) at National Research Centre (NRC).
- 29 October 2025
- Published by Egyptian Knowledge Bank in Egyptian Pharmaceutical Journal
Open AccessGenetic insights and therapeutic implications in Egyptian patients with Fabry Disease
BackgroundFabry disease (FD) is an X-linked lysosomal storage disorder resulting from pathogenic variants in the α-galactosidase (GLA) gene, leading to deficiency in “α-galactosidase A” (GLA) activity. This enzyme deficiency leads to progressive accumulation of glycosphingolipids in various tissues and organs. ObjectivesThis study aims to clinical, biochemical, and molecular diagnosis for three unrelated Egyptian families with Fabry disease.Patients and methods The GLA enzyme activity was measured in 3 males from 3 unrelated families. The GLA activity was measured by using the fluorogenic substrate “4-methylumbelliferyl-α-D-galactopyranoside” and the diagnosis of FD was established by GLA deficiency. The patients presented with variable renal, cardiac, ocular and dermatological manifestations. History and pedigree was done for 3 families. Molecular analysis of GLA gene was performed for 3 patients, the mother, two daughters and the sister of P1, the mother, wife and daughter of P2, and the mother, brother, and cousin of P3. Genetic tests by PCR of the gene-coding region followed by Sanger sequencing. Results We revealed 3 previously reported GLA variants in 3 Fabry families. Family 1, a nonsense variant c.627G>A, p.W209* was identified in patient 1 and in one of the patient’s daughters. In Family 2, a splice-site variant c.370-2A>G was detected in patient 2 and in his mother and daughter. In Family 3, a missense variant c.334C>T, p.R112C was detected in patient 3.Conclusion This study expands the molecular genetic spectrum of the GLA gene associated with Egyptian FD patients. Our findings highlighted the importance of early diagnosis, proper genetic counseling and therapy for FD patients. To the best of our knowledge, the present study is the first delineating the GLA variant profile in Egyptian FD patients. The patients are currently receiving Enzyme Replacement Therapy (ERT) at National Research Centre (NRC).
- Open Access
- 13 March 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-9
Biochemical and mutational analyses of HEXA in a cohort of Egyptian patients with infantile Tay-Sachs disease. Expansion of the mutation spectrum
Background: Tay-Sachs disease (TSD), an autosomal recessively inherited neurodegenerative lysosomal storage disease, reported worldwide with a high incidence among population of Eastern European and Ashkenazi Jewish descent. Mutations in the alpha subunit of HEXA that encodes for the β-hexosaminidase-A lead to deficient enzyme activity and TSD phenotype. This study is the first to highlight the HEXA sequence variations spectrum in a cohort of Egyptian patients with infantile TSD. Results: This study involved 13 Egyptian infant/children patients presented with the infantile form of TSD, ten of the 13 patients were born to consanguineous marriages. β-hexosaminidase-A enzyme activity was markedly reduced in the 13 patients with a mean activity of 3 µmol/L/h ± 1.56. Sanger sequencing of the HEXA’ coding regions and splicing junctions enabled a detection rate of ~ 62% (8/13) in our patients revealing the molecular defects in eight patients; six homozygous-mutant children (five of them were the product of consanguineous marriages) and two patients showed their mutant alleles in heterozygous genotypes, while no disease-causing mutation was identified in the remaining patients. Regulatory intragenic mutations or del/dup may underlie the molecular defect in those patients showing no relevant pathogenic sequencing variants or in the two patients with a heterozygous genotype of the mutant allele. This research identified three novel, likely pathogenic variants in association with the TSD phenotype; two missense, c.920A > C (E307A) and c.952C > G (H318D) in exon 8, and a single base deletion c.484delG causing a frameshift E162Rfs*37 (p.Glu162ArgfsTer37) in exon 5. Three recurrent disease-causing missense mutations; c.1495C > T (R499C), c.1511G > A(R504H), and c.1510C > T(R504C) in exon 13 were identified in five of the eight patients. None of the variants was detected in 50 healthy Egyptians’ DNA. Five variants, likely benign or of uncertain significance, S3T, I436V, E506E, and T2T, in exons 1, 11,13, & 1 were detected in our study. Conclusions: For the proper diagnostics, genetic counseling, and primary prevention, our study stresses the important role of Next Generation Sequencing approaches in delineating the molecular defect in TSD-candidate patients that showed negative Sanger sequencing or a heterozygous mutant allele in their genetic testing results. Interestingly, the three recurrent TSD associated mutations were clustered on chromosome 13 and accounted for 38% of the HEXA mutations detected in this study. This suggested exon 13 as the first candidate for sequencing screening in Egyptian patients with infantile TSD. Larger studies involving our regional population are recommended, hence unique disease associated pathogenic variations could be identified.
- 13 March 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-9
Open AccessBiochemical and mutational analyses of HEXA in a cohort of Egyptian patients with infantile Tay-Sachs disease. Expansion of the mutation spectrum
Background: Tay-Sachs disease (TSD), an autosomal recessively inherited neurodegenerative lysosomal storage disease, reported worldwide with a high incidence among population of Eastern European and Ashkenazi Jewish descent. Mutations in the alpha subunit of HEXA that encodes for the β-hexosaminidase-A lead to deficient enzyme activity and TSD phenotype. This study is the first to highlight the HEXA sequence variations spectrum in a cohort of Egyptian patients with infantile TSD. Results: This study involved 13 Egyptian infant/children patients presented with the infantile form of TSD, ten of the 13 patients were born to consanguineous marriages. β-hexosaminidase-A enzyme activity was markedly reduced in the 13 patients with a mean activity of 3 µmol/L/h ± 1.56. Sanger sequencing of the HEXA’ coding regions and splicing junctions enabled a detection rate of ~ 62% (8/13) in our patients revealing the molecular defects in eight patients; six homozygous-mutant children (five of them were the product of consanguineous marriages) and two patients showed their mutant alleles in heterozygous genotypes, while no disease-causing mutation was identified in the remaining patients. Regulatory intragenic mutations or del/dup may underlie the molecular defect in those patients showing no relevant pathogenic sequencing variants or in the two patients with a heterozygous genotype of the mutant allele. This research identified three novel, likely pathogenic variants in association with the TSD phenotype; two missense, c.920A > C (E307A) and c.952C > G (H318D) in exon 8, and a single base deletion c.484delG causing a frameshift E162Rfs*37 (p.Glu162ArgfsTer37) in exon 5. Three recurrent disease-causing missense mutations; c.1495C > T (R499C), c.1511G > A(R504H), and c.1510C > T(R504C) in exon 13 were identified in five of the eight patients. None of the variants was detected in 50 healthy Egyptians’ DNA. Five variants, likely benign or of uncertain significance, S3T, I436V, E506E, and T2T, in exons 1, 11,13, & 1 were detected in our study. Conclusions: For the proper diagnostics, genetic counseling, and primary prevention, our study stresses the important role of Next Generation Sequencing approaches in delineating the molecular defect in TSD-candidate patients that showed negative Sanger sequencing or a heterozygous mutant allele in their genetic testing results. Interestingly, the three recurrent TSD associated mutations were clustered on chromosome 13 and accounted for 38% of the HEXA mutations detected in this study. This suggested exon 13 as the first candidate for sequencing screening in Egyptian patients with infantile TSD. Larger studies involving our regional population are recommended, hence unique disease associated pathogenic variations could be identified.
- Open Access
- 1 December 2021
- Published by Elsevier in Journal of Genetic Engineering and Biotechnology
- Vol. 19 (1) , 111-10
Quaternary diagnostics scheme for mucolipidosis II and detection of novel mutation in GNPTAB gene
- 1 December 2021
- Published by Elsevier in Journal of Genetic Engineering and Biotechnology
- Vol. 19 (1) , 111-10
Open AccessQuaternary diagnostics scheme for mucolipidosis II and detection of novel mutation in GNPTAB gene
- 23 November 2015
- Published by Hindawi Limited in Human Mutation
- Vol. 37 (2) , 170-174
PEX6 is Expressed in Photoreceptor Cilia and Mutated in Deafblindness with Enamel Dysplasia and Microcephaly
Deafblindness is part of several genetic disorders. We investigated a consanguineous Egyptian family with two siblings affected by congenital hearing loss and retinal degeneration, initially diagnosed as Usher syndrome type 1. At teenage, severe enamel dysplasia, developmental delay, and microcephaly became apparent. Genome‐wide homozygosity mapping and whole‐exome sequencing detected a homozygous missense mutation, c.1238G>T (p.Gly413Val), affecting a highly conserved residue of peroxisomal biogenesis factor 6, PEX6. Biochemical profiling of the siblings revealed abnormal and borderline plasma phytanic acid concentration, and cerebral imaging revealed white matter disease in both. We show that Pex6 localizes to the apical extensions of secretory ameloblasts and differentiated odontoblasts at early stages of dentin synthesis in mice, and to cilia of retinal photoreceptor cells. We propose PEX6, and possibly other peroxisomal genes, as candidate for the rare cooccurrence of deafblindness and enamel dysplasia. Our study for the first time links peroxisome biogenesis disorders to retinal ciliopathies.
- 23 November 2015
- Published by Hindawi Limited in Human Mutation
- Vol. 37 (2) , 170-174
PEX6 is Expressed in Photoreceptor Cilia and Mutated in Deafblindness with Enamel Dysplasia and Microcephaly
Deafblindness is part of several genetic disorders. We investigated a consanguineous Egyptian family with two siblings affected by congenital hearing loss and retinal degeneration, initially diagnosed as Usher syndrome type 1. At teenage, severe enamel dysplasia, developmental delay, and microcephaly became apparent. Genome‐wide homozygosity mapping and whole‐exome sequencing detected a homozygous missense mutation, c.1238G>T (p.Gly413Val), affecting a highly conserved residue of peroxisomal biogenesis factor 6, PEX6. Biochemical profiling of the siblings revealed abnormal and borderline plasma phytanic acid concentration, and cerebral imaging revealed white matter disease in both. We show that Pex6 localizes to the apical extensions of secretory ameloblasts and differentiated odontoblasts at early stages of dentin synthesis in mice, and to cilia of retinal photoreceptor cells. We propose PEX6, and possibly other peroxisomal genes, as candidate for the rare cooccurrence of deafblindness and enamel dysplasia. Our study for the first time links peroxisome biogenesis disorders to retinal ciliopathies.
- Open Access
- 1 April 2015
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 16 (2) , 159-163
Prenatal genetic testing, counseling and follow-up of 33 Egyptian pregnant females with history of mucopolysaccharidoses
- 1 April 2015
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 16 (2) , 159-163
Open AccessPrenatal genetic testing, counseling and follow-up of 33 Egyptian pregnant females with history of mucopolysaccharidoses
- Open Access
- 1 October 2014
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 15 (4) , 379-385
Fifteen years experience: Egyptian metabolic lab
- 1 October 2014
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 15 (4) , 379-385
Open AccessFifteen years experience: Egyptian metabolic lab
- 1 June 2014
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 15 (2) , 63-67
Glycogen storage disease type III in Egyptian children: A single centre clinico-laboratory study
- 1 June 2014
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 15 (2) , 63-67
Glycogen storage disease type III in Egyptian children: A single centre clinico-laboratory study
- 1 January 2014
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 115 (05) , 300-306
Disorders associated with abnormal acylcarnitine profile among high risk Egyptian children
Disorders associated with abnormal acylcarnitine profile among high risk Egyptian children
- 1 January 2014
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 115 (05) , 300-306
Disorders associated with abnormal acylcarnitine profile among high risk Egyptian children
Disorders associated with abnormal acylcarnitine profile among high risk Egyptian children
- 1 January 2012
- Vol. 23 (2) , 175-84
A report of three patients with MMP2 associated hereditary osteolysis.
Osteolysis syndromes are rare hereditary disorders characterized by destruction and resorption of affected bones. The current study adds three new patients from two unrelated consanguineous families with a severe form of inherited osteolysis. Clinical examination, radiological, biochemical, ultrastructural and molecular studies were conducted. Clinical and radiological studies suggested the diagnosis of Torg-Winchester syndrome. The three affected patients were homozygous for novel MMP2 gene mutations which confirmed the diagnosis. Our patients are the first to be reported from Egypt thus, supporting the pan ethnic nature of the disease.
- 1 January 2012
- Vol. 23 (2) , 175-84
A report of three patients with MMP2 associated hereditary osteolysis.
Osteolysis syndromes are rare hereditary disorders characterized by destruction and resorption of affected bones. The current study adds three new patients from two unrelated consanguineous families with a severe form of inherited osteolysis. Clinical examination, radiological, biochemical, ultrastructural and molecular studies were conducted. Clinical and radiological studies suggested the diagnosis of Torg-Winchester syndrome. The three affected patients were homozygous for novel MMP2 gene mutations which confirmed the diagnosis. Our patients are the first to be reported from Egypt thus, supporting the pan ethnic nature of the disease.